MTSR
Metsera, Inc.70.50
-0.25-0.35%
Nov 13, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
7.43BP/E (TTM)
-Basic EPS (TTM)
-2.99Dividend Yield
0%Recent Filings
8-K
8-K
8-K
Metsera picks Novo over Pfizer
Metsera declared Novo Nordisk's unsolicited $56.50 per share cash proposal a superior offer to its Pfizer merger, triggering a four-day negotiation window for Pfizer to match. The two-step deal includes immediate cash and preferred stock issuance for 50% ownership, followed by a merger with up to $21.25 in CVRs tied to obesity drug milestones by 2031, valuing Metsera at ~$9.1 billion. This boosts immediate shareholder value but hinges on regulatory and shareholder approvals amid integration risks.
8-K
Positive MET-097i Phase 2b results
Metsera announced positive Phase 2b topline data for MET-097i, its ultra-long acting GLP-1 receptor agonist, showing placebo-subtracted mean weight loss of up to 14.1% after 28 weekly doses in VESPER-1, with no plateau observed. Tolerability stood out, with minimal diarrhea and risk differences of 13% for nausea and 11% for vomiting at the highest dose in VESPER-3 after titration. MET-097i advances as the backbone for multiple programs. Phase 3 trials start late 2025. Data could differ from expectations.
8-K
Metsera Q2 loss, pipeline progress
Metsera reported Q2 2025 financials, posting a $68.7 million net loss amid ramped-up R&D spending of $60.5 million, yet bolstered its cash pile to $530.9 million—enough runway into 2027. Pipeline advances shine: MET-233i monotherapy hit 8.4% weight loss in five weeks with a 19-day half-life, while VESPER-1 and interim VESPER-3 data for MET-097i loom in September. Cash fuels bold bets. Clinical timelines risk delays from trial hurdles.
ALT
Altimmune, Inc.
5.03-0.25
MBX
MBX Biosciences, Inc.
27.75-0.63
MCRB
Seres Therapeutics, Inc.
16.20+0.30
MRKR
Marker Therapeutics, Inc.
1.27-0.12
MRNA
Moderna, Inc.
29.89-0.03
MRSN
Mersana Therapeutics, Inc.
29.05+0.46
MTVA
MetaVia Inc.
8.14-0.17
SEPN
Septerna, Inc.
26.23-0.95
TELO
Telomir Pharmaceuticals, Inc.
1.40-0.02
TERN
Terns Pharmaceuticals, Inc.
42.92-1.09